Phase II
The American Society of Hematology Annual Meeting is always chock full of interesting research and development stories. Here’s a look at some of the highlights of the meeting so far, which is continuing today.
Asthma drug failed to show a statistically clinical improvement in controlling asthma, Dynavax said.
Elto Pharma is developing eltoprazine, which is in Phase IIb clinical development for Parkinson’s disease levodopa-induced dyskinesias, or Parkinson’s LID.
Trial of CD22-targeting antibody drug conjugate being led by The University of Texas MD Anderson Cancer Center
The active pharmaceutical ingredients (API) will be produced according to GMP requirements in a clean room rented from Accessia Pharma, a provider of high-quality pharmaceutical infrastructures
New therapeutic combination is expected to be generally applicable to many solid tumors with high unmet medical need
MorphoSys AG announced today that its licensee Janssen Research & Development, LLC (Janssen) initiated a phase 2 clinical study of guselkumab in patients with moderate to severe hidradenitis suppurativa (HS), a chronic skin disease also known as acne inversa.
Overall response rate at 28 days of 60%, complete response rate of 50%
Immunicum AB announced today that it has entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, and Pfizer to evaluate its lead product, ilixadencel, an off-the-shelf cell-based cancer immune primer, in combination with avelumab*, a human anti-PD-L1 monoclonal antibody, in a planned multi-indication Phase Ib/II clinical trial.
DCCR treatment resulted in statistically significant decreases in body fat in subjects with Prader-Willi Syndrome
PRESS RELEASES